India IPO Pipeline SEBI Regulatory Filings — October 31, 2026

Revenue from operations declined 32.1% to ₹407.87 Lakh in H1 FY27 from ₹600.87 Lakh in the prior full-year period, indicating a severe demand collapse

Net loss of ₹143.39 Lakh versus a profit of ₹30.31 Lakh a year earlier, a swing of ₹173.70 Lakh, with EPS turning negative at ₹(4.02) from ₹5.21

Shareholders' funds fell 13.6% to ₹939.86 Lakh from ₹1,088.25 Lakh as reserves dropped 20.5% to ₹576.23 Lakh from ₹724.62 Lakh, signaling capital erosion

IPO proceeds of ₹1243.00 Lakh fully deployed with ₹500 Lakh each toward software purchase and working capital, but the resulting losses suggest poor capital efficiency

76.5% of IPO proceeds (₹307.50 Lakh of ₹402.00 Lakh) utilized with no deviation, demonstrating disciplined capital deployment

Full utilization of General Corporate Expenses (₹19.55 Lakh) and Issue Related Expenses (₹45.00 Lakh) indicates adherence to stated objects

Partial deployment in machinery (₹194.95 Lakh of ₹262.45 Lakh) and medical tourism portal (₹48.00 Lakh of ₹75.00 Lakh) suggests ongoing capex for growth

No deviation in IPO proceeds utilization, with only ₹8.21 Lakh parked in escrow, reflecting compliance but not operational success

Both companies show no insider trading activity or pledges in the enriched data, limiting management conviction signals

Absence of forward-looking guidance from both filings reduces visibility into future performance and catalysts

Revenue more than halved YoY (down 32% on a comparable basis) and net loss of ₹143.39 Lakh raises going-concern concerns if trend persists

Reserves declined 20.5% to ₹576.23 Lakh, and shareholders' funds fell 13.6%, indicating rapid cash burn post-IPO

EPS turned negative at ₹(4.02) from ₹5.21, a 177% decline, with no clear path to profitability disclosed

Despite full deployment of ₹1243 Lakh IPO proceeds, the company swung to a loss, suggesting misallocation or adverse market conditions

23.5% of IPO proceeds (₹94.50 Lakh) remain unutilized after two years since allotment (Aug 2024), indicating slow project execution

Medical tourism portal development only 64% complete (₹48 Lakh of ₹75 Lakh) may face delays, impacting growth prospects

Both filings lack insider activity data, which could signal low management confidence or disclosure gaps

No forward-looking guidance provided, increasing uncertainty for investors

Disciplined capital deployment with 76.5% utilization and no deviation could appeal to investors seeking compliant small-cap healthcare plays

Remaining ₹94.50 Lakh deployment in machinery and portal could drive future revenue growth if completed on schedule

Deep value potential if turnaround occurs, given full deployment of IPO funds and low escrow balance; watch for restructuring or new strategy

Negative sentiment may have overpriced the stock; any positive operational update could trigger a rebound

Post-IPO compliance filings provide transparency; investors can screen for companies with high utilization rates and low deviation as quality signals

Small-cap IPO graduates with strong capital discipline (like Broach) may outperform in a risk-averse market

Broach utilized 76.5% of proceeds with no deviation, while Finelistings fully deployed but suffered losses, highlighting that deployment alone does not guarantee success; operational execution is key

Finelistings' revenue collapse and loss underscore the vulnerability of small-cap IPOs to market downturns, with reserves eroding quickly

Broach's partial deployment in medical equipment (74% complete) and portal (64% complete) suggests ongoing capex in healthcare, albeit at a slow pace

Both filings emphasize no deviation in IPO proceeds, reflecting regulatory scrutiny and improved disclosure standards post-SEBI reforms

Monitor for any restructuring, cost-cutting, or revenue recovery in Q3 FY27; next board meeting likely Jan 2027

Track utilization of remaining ₹94.50 Lakh, especially machinery and portal completion, by Q3 FY27 filing

Watch for insider activity or pledging disclosures, currently absent, which could signal management confidence

Monitor for any deviation in future quarters as unutilized funds decrease

Upcoming IPO listings in the India pipeline for Q4 2026; watch for pricing and subscription trends

SEBI may tighten post-IPO disclosure norms; monitor for any new guidelines affecting small-cap IPOs